News

The University of Cambridge and AstraZeneca have a long history of scientific collaboration. In 2013, AstraZeneca’s decision to move its global headquarters and new strategic R&D centre to Cambridge started a new chapter of partnership.AstraZeneca chose Cambridge – the largest life science cluster in Europe – for its access to world-leading academi…

Cambridge University has been selected as a partner in a key Government initiative to attract more of the world’s best research talent to the UK.Because of its track record in recruiting and supporting top international researchers, the University will get a share of the new £54 million Global Talent Fund, along with 12 of the UK’s leading universi…

Cambridge researchers are leading drug discovery to develop safer, more effective treatments for the millions of people affected by Alzheimer’s and other neurodegenerative diseases.According to Alzheimer’s Research UK, if nothing changes one in two of us will be affected by dementia in our lifetime, either by caring for someone with the condition, …

Many life-saving drugs directly interact with DNA to treat diseases such as cancer, but scientists have struggled to detect how and why they work – until now.In apaperpublished in the journalNature Biotechnology, University of Cambridge researchers have outlined a new DNA sequencing method that can detect where and how small molecule drugs interact…

Cambridge scientists have managed to identify and kill those breast cancer cells that evade standard treatments in a study in mice. The approach is a step towards the development of new treatments to prevent relapse in patients.Tumours are incredibly complex, made up of many different types of tumour cells – and some of these cells are able to evad…

A drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe COVID-19, despite this approach being offered to patients, a UK-wide trial, led by Addenbrooke’s Hospital and the University of Cambridge has found.This finding is important because it will prevent unnecessary harm occurring to people for no ben…

Cambridge researchers will play a key role in clinical trials of a new treatment that involves transplanting healthy nerve cells into the brains of patients with Parkinson’s disease.This could transform the way we treat Parkinson’s diseaseRoger BarkerThe Swedish Medical Products Agency has granted approval for the trial to proceed; ethical approval…

Researchers say a ‘human bottleneck’, due to historical cuts in public health funding, delayed the UK’s scale-up of COVID-19 testing in the early stages of the country’s pandemic response.A pandemic like COVID-19 is guaranteed to happen again at some point.Jordan SkittrallThe researchers, who were on the front line of the UK’s early response to COV…

Five Cambridge researchers join the community of more than 1,900 leading life scientists in Europe and beyond today as the European Molecular Biology Organisation (EMBO) announces its newly-elected Members. EMBO Members are recognised for their outstanding achievements in the life sciences. The newly elected members reside in 22 countries. The 58 n…

The University of Cambridge has formed a new agreement with AstraZeneca for the global biopharmaceuticals company to fund 55 additional PhD studentships over the next five years, starting in October 2022. Over the last 20 years, AstraZeneca has funded more than 100 PhD students from the University as part of a longstanding partnership between the t…

A major new institute opens today, bringing together the largest concentration of scientists and clinicians in heart and lung medicine in Europe.On 18 August 1979, Keith Castle – despite being described by surgeon Sir Terence English as "not an ideal patient from a medical point of view" – made history, becoming the first person in the UK to underg…

Long term use of implantable medical devices- such as pacemakers and cochlear implants- is hampered by the body's reaction to foreign bodies. now, in a study in mice, a team led by scientists at the University of Cambridge has shown that this reaction can be dramatically reduced by incorporating an anti-inflammatory drug into the silicone implant.C…

Spin-off company Cambridge Raman Imaging Ltd. and the Cambridge Graphene Centre will lead ‘CHARM’ project, recently awarded with €3.2 millionFunding from the European Union is an integral part of the Cambridge Graphene Centre’s successAndrea FerrariThe European Innovation Council (EIC) has awarded the first Transition Grant to Cambridge’s Departmen…

Defective mitochondria – the ‘batteries’ that power the cells of our bodies – could in future be repaired using gene-editing techniques. Scientists at the University of Cambridge have shown that it is possible to modify the mitochondrial genome in live mice, paving the way for new treatments for incurable mitochondrial disorders.[This] shows that, …

Cambridge spin-out Zetta Genomics has raised £2.5 million in new seed funding from Nina Capital, APEX Medical and Cambridge Enterprise to advance its genomic data management technology and power the discovery and delivery of precision medicine at scale.XetaBase is built on the open-source OpenCB platform, the first proven big data system optimised …